Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 03, 2015 6:24 PM ET


Company Overview of Theravance Inc.

Executive Profile

George B. Abercrombie R.Ph., MBA

Senior Vice President of Corporate Partnerships & Commercial, Theravance Inc.
AgeTotal Calculated CompensationThis person is connected to 4 Board Members in 4 different organizations across 10 different industries.

See Board Relationships
As of Fiscal Year 2014


Mr. George B. Abercrombie, R.Ph., MBA, has been Senior Vice President of Corporate Partnerships & Commercial at Theravance Inc. since June 2014. Mr. Abercrombie has more than 30 years experience as a Business Leader in the pharmaceutical industry. He has substantial expertise in sales and marketing, executive sales management and business development. Mr. Abercrombie served as the Chief Executive Officer and President of Roche Laboratories, Inc. Mr. Abercrombie served ...

Corporate Headquarters

951 Gateway Boulevard
South San Francisco, California 94080

United States

Phone: 650-238-9600
Fax: --

Board Members Memberships

Director and Member of Audit Committee
Non-Executive Chairman, Member of Audit Committee, Member of Corporate Governance & Nominating Committee and Member of Compensation Committee


Harvard Business School
University Of North Carolina At Chapel Hill

Other Affiliations

Annual Compensation

Total Annual Compensation$219,167

Stocks Options

Restricted Stock Awards$293,200
All Other Compensation$500
Unexercisable Options$100,000
Total Number of Options$100,000

Total Compensation

Total Annual Cash Compensation$389,667
Total Short Term Compensation$219,167
Other Long Term Compensation$293,700
Total Calculated Compensation$1,899,507

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup


Howard W. Robin Chief Executive Officer, President and Director
Nektar Therapeutics
Peter M. Hecht Ph.D. Co-Founder, Chief Executive Officer and Director
Ironwood Pharmaceuticals, Inc.
Mark R. Baker J.D.Chief Executive Officer, Director and Member of Science & Strategy Committee
Progenics Pharmaceuticals, Inc.
Peter S. Greenleaf Chief Executive Officer and Director
Sucampo Pharmaceuticals, Inc.
Richard Martin Steeves Ph.D.Group Chief Executive Officer, Member of Senior Executive Board and Executive Director
Synergy Health plc
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Theravance Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at